A Phase 2 Study to Assess the Effect of TD-9855 in Subjects With Neurogenic Orthostatic Hypotension
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2017
At a glance
- Drugs TD 9855 (Primary)
- Indications Orthostatic hypotension
- Focus Therapeutic Use
- Sponsors Theravance Biopharma
- 08 Aug 2017 Data from this trial are expected in 1H 2018, according to a Theravance biopharma media release.
- 28 Jul 2017 Planned End Date changed from 1 Mar 2017 to 1 Jun 2018.
- 28 Jul 2017 Planned primary completion date changed from 1 Jan 2017 to 1 May 2018.